Results 81 to 90 of about 9,615 (165)
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib
Introduction Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase, has altered the treatment perspective of chronic lymphocytic leukemia and showed modest activity against several types of non-Hodgkin's lymphomas.
Umit, Elif +13 more
core +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Ibrutinib: From Molecule to Medicine
İbrutinib: Molekülden İlacaBruton tirozin kinaz (BTK) inhibitörü Ibrutinib (PCI-32765), BTK üzerine irreversibl kovalan bağlanarak BCR aktivitesini yönlendiren yeni bir hedeflenmiş tedavi ajanıdır.
ÜNAL, Ali +12 more
core +1 more source
Bruton tyrosine kinase inhibitors and cardiovascular adverse events
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli +4 more
wiley +1 more source
There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β2‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids ...
Ian M. Adcock
wiley +1 more source
HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
Ibrutinib is a major new addition to the therapeutic armamentarium for chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and chronic graft versus host disease. Though ibrutinib has proven to be a revolutionary new small
Mark R. Wallace
doaj +1 more source
Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia [PDF]
B-cell receptor (BCR) signaling is essential for chronic lymphocytic leukemia (CLL) cell survival. Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets.
Jain, Nitin +3 more
core +1 more source
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao +8 more
wiley +1 more source
IntroductionIbrutinib, widely used in leukemia treatment, has been implicated in sensorineural hearing loss; however, its underlying mechanisms remain unclear.MethodsThis study investigated the impact of ibrutinib on hearing using HEI-OC1 cells, cochlear
Yuhua Zhang +9 more
doaj +1 more source
ABSTRACT Loncastuximab tesirine (LT) is an antibody‐drug conjugate (ADC), a novel class of therapeutics that combines a target‐specific monoclonal antibody with a cytotoxic agent via a chemical linker. LT has been approved in the United States as therapy for relapsed or refractory diffuse large B‐cell lymphoma (DLBCL).
Daniella Jaguan +2 more
wiley +1 more source

